How antibiotics are supposed to work for H. pylori
The standard H. pylori treatment uses two antibiotics simultaneously — typically clarithromycin plus amoxicillin, combined with a proton pump inhibitor (PPI). The logic is that attacking the bacteria from two different biochemical angles reduces the chance of resistance. Eradication rates for triple therapy, when it works, are around 70–90%.[2]
The problem is when it doesn't work.
What antibiotic resistance means for H. pylori
Antibiotic resistance happens when bacteria develop genetic mutations that allow them to survive exposure to antibiotics. H. pylori is particularly prone to this — it has a high mutation rate, and clarithromycin resistance in particular is now widespread.[1]
Why H. pylori resistance is rising in India
There are three main reasons:
- Over-the-counter antibiotic availability. Antibiotics are widely available without prescriptions in India.[3] This leads to frequent, incomplete antibiotic courses — each one increasing the chances that resistant strains survive.
- Prior antibiotic use for other conditions. If you've taken clarithromycin or amoxicillin for a respiratory infection, your H. pylori may already have been exposed to it — selecting for resistant variants before you ever start formal H. pylori treatment.
- Subtherapeutic dosing. Short courses at lower doses — common when people stop taking antibiotics when they feel better — allow bacteria to survive exposure without being eliminated, accelerating resistance development.
What to do if antibiotics aren't clearing your H. pylori
First: go back to your doctor. Do not self-medicate. A doctor can:
- Test for antibiotic sensitivity before prescribing — this tells you which antibiotics the bacteria is actually susceptible to
- Prescribe quadruple therapy — a four-drug combination that is more effective against resistant strains
- Extend the treatment duration — 14-day courses have higher eradication rates than 7-day courses
Bismuth-based quadruple therapy is available in India and is recommended as a second-line option when triple therapy fails. Your doctor can prescribe it. It has higher success rates against clarithromycin-resistant strains.
The role of mucosal support alongside antibiotic treatment
Even when antibiotics successfully clear H. pylori, there is a window of vulnerability. The stomach lining that H. pylori damaged doesn't automatically repair once the bacteria is gone. And the microbiome disrupted by the antibiotics takes time to recover.
Flavonoids have a specific role to play here. Beyond their direct activity against H. pylori (inhibiting urease, reducing adhesion), they create the environment for stomach lining recovery that follows successful bacterial clearance. Antibiotics target the bacteria. Flavonoids support the recovery environment.
Antibiotic resistance doesn't mean the bacteria can't be cleared — it means the choice of antibiotics matters. Sensitivity testing, quadruple therapy, and adequate treatment duration are the right tools. Mucosal support alongside treatment gives the stomach lining the best conditions to recover once the bacteria is addressed.
What about herbal alternatives to antibiotics for H. pylori?
Several plant compounds have shown antimicrobial activity against H. pylori in laboratory and early clinical studies — including quercetin, myricetin, and licorice-derived compounds. However, the current evidence does not support herbal compounds as a replacement for antibiotics in active, symptomatic H. pylori infection. They are most appropriately used for:
- Supporting the stomach environment after antibiotic treatment
- Reducing the likelihood of reinfection
- Creating the environment for stomach lining recovery
- Cases where antibiotic treatment has been attempted and failed
References
- Thyagarajan SP, Ray P, Das BK, et al. Geographical difference in antimicrobial resistance pattern of Helicobacter pylori clinical isolates from Indian patients. Indian Journal of Medical Research. 2003;117:27–32. PMID 12567118. Foundational Indian study documenting high clarithromycin resistance rates — the basis for the 40–60% figure cited in this article.
- Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection — the Maastricht VI/Florence Consensus Report. Lancet. 2022;400(10356):955–971. PMID 35569473. Current international treatment consensus. Defines triple therapy eradication rates and recommends quadruple therapy as second-line in high-resistance regions.
- Mukhopadhyay AK, Kersulyte D, Jeong JY, et al. Distinctiveness of genotypes of Helicobacter pylori in Calcutta, India. Journal of Bacteriology. 2000;182(11):3219–3227. PMC94508. Documents the molecular basis of clarithromycin resistance in Indian H. pylori strains, confirming widespread resistance driven by prior antibiotic exposure.
The 40–60% clarithromycin resistance rate is consistent with multiple Indian clinical studies and significantly higher than Western European rates (typically 15–20% per the Maastricht VI Consensus). The Maastricht VI Consensus recommends regions with >15% clarithromycin resistance avoid clarithromycin-based triple therapy as first line — a threshold India substantially exceeds. The TumGard India Gut Health Report 2026 corroborates this: 67% of buyers had been symptomatic for over a year, suggesting many had undergone prior antibiotic courses without confirmed eradication.